ORMP - Oramed Pharmaceuticals Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue641---
Cost of Revenue490---
Gross Profit151---
Operating Expenses
Research Development----
Selling General and Administrative----
Non Recurring----
Total Operating Expenses10,6517,3835,9064,304
Operating Income or Loss-10,010-7,383-5,906-4,304
Income from Continuing Operations
Total Other Income/Expenses Net----
Earnings Before Interest and Taxes-10,010-7,383-5,906-4,304
Interest Expense-65-6-6-6
Income Before Tax----
Income Tax Expense1,335-14-205
Minority Interest----
Net Income From Continuing Ops----
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-10,964-7,232-5,696-4,232
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares----